Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

In Vivo Purging

Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab

Summary:

The main aim of this paper was to compare results of Genescan and real-time PCR methods in order to detect contamination in harvests from patients with follicular lymphoma. The secondary goal was to evaluate the efficacy of Rituximab as an in vivo purging agent. A total of 23 patients had been treated with CHOP followed by either high-dose therapy (12 patients) or high-dose plus Rituximab (11 patients), both followed by autologous transplantation. Results show that 86% of harvests from patients treated whith Rituximab were PCR-negative compared to 14.3% from controls. Real-time PCR was more sensitive than Genescan PCR; quantitative analysis revealed a correlation between the amount of contamination in the harvests and relapse after transplantation. Whereas all patients reinfused with negative aphereses achieved complete remission and showed a significantly better 5-year PFS (100%) compared to those reinfused with contaminated samples (41%), a very low amount of contamination does not appear to negatively affect outcome, suggesting that determination of a cutoff in the contamination level of harvests could be useful. Results suggest that real-time PCR is superior to Genescan PCR to select transplantable harvests and confirm the ability of Rituximab as an in vivo purging tool for follicular lymphoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of BCL2 have residual containing the BCL2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280.

    CAS  Google Scholar 

  2. Freedman AS, Neuberg D, Mauch P et al. Long-term follow up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  Google Scholar 

  3. Cleary ML, Sklar J . Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439–7443.

    Article  CAS  Google Scholar 

  4. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724–731.

    CAS  Google Scholar 

  5. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

    Article  CAS  Google Scholar 

  6. Mehra S, Messner H, Minden M, Chaganti RS . Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 2002; 33: 225–234.

    Article  CAS  Google Scholar 

  7. Ririe KM, Rasmussen RP, Wittwer CT . Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Analytical Biochemistry 1997; 245: 154–160.

    Article  CAS  Google Scholar 

  8. Decaudin D, Lepage E, Brousse N et al. Low-grade follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the Groupe d'etude des lymphomes de l'adulte. J Clin Oncol 1999; 17: 2499–2505.

    Article  CAS  Google Scholar 

  9. Sacchi S, Federico M, Vitolo U et al. Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958.

    CAS  PubMed  Google Scholar 

  10. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862.

    Article  CAS  Google Scholar 

  11. Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235.

    Article  CAS  Google Scholar 

  12. Hirt C, Dolken G . Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant 2000; 25: 419–426.

    Article  CAS  Google Scholar 

  13. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.

    CAS  Google Scholar 

  14. Moos M, Schulz R, Cremer F et al. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995; 13 (Suppl 3): 42–51.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This paper is part of the molecular program of Italian Group for Lymphoma Study (GISL).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galimberti, S., Guerrini, F., Morabito, F. et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplant 32, 57–63 (2003). https://doi.org/10.1038/sj.bmt.1704102

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704102

Keywords

This article is cited by

Search

Quick links